1 Study Coverage 1.1 Recombinant Protein Drug R&D Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Introduction 1.2 Global Recombinant Protein Drug R&D Outlook 2017 VS 2022 VS 2028 1.2.1 Global Recombinant Protein Drug R&D Market Size for the Year 2017-2028 1.2.2 Global Recombinant Protein Drug R&D Market Size for the Year 2017-2028 1.3 Recombinant Protein Drug R&D Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Recombinant Protein Drug R&D in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Recombinant Protein Drug R&D Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Recombinant Protein Drug R&D Market Dynamics 1.4.1 Recombinant Protein Drug R&D Industry Trends 1.4.2 Recombinant Protein Drug R&D Market Drivers 1.4.3 Recombinant Protein Drug R&D Market Challenges 1.4.4 Recombinant Protein Drug R&D Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Recombinant Protein Drug R&D by Type 2.1 Recombinant Protein Drug R&D Market Segment by Type 2.1.1 Peptide Hormones 2.1.2 Hematopoietic Factor 2.1.3 Cytokines 2.1.4 Plasma Protein Factor 2.1.5 Recombinase 2.1.6 Fusion Protein 2.1.7 Other 2.2 Global Recombinant Protein Drug R&D Market Size by Type (2017, 2022 & 2028) 2.3 Global Recombinant Protein Drug R&D Market Size by Type (2017-2028) 2.4 United States Recombinant Protein Drug R&D Market Size by Type (2017, 2022 & 2028) 2.5 United States Recombinant Protein Drug R&D Market Size by Type (2017-2028) 3 Recombinant Protein Drug R&D by Application 3.1 Recombinant Protein Drug R&D Market Segment by Application 3.1.1 Diabetes 3.1.2 Dwarfism 3.1.3 Hemophilia 3.1.4 Heart Disease 3.1.5 Cancer 3.1.6 Other 3.2 Global Recombinant Protein Drug R&D Market Size by Application (2017, 2022 & 2028) 3.3 Global Recombinant Protein Drug R&D Market Size by Application (2017-2028) 3.4 United States Recombinant Protein Drug R&D Market Size by Application (2017, 2022 & 2028) 3.5 United States Recombinant Protein Drug R&D Market Size by Application (2017-2028) 4 Global Recombinant Protein Drug R&D Competitor Landscape by Company 4.1 Global Recombinant Protein Drug R&D Market Size by Company 4.1.1 Top Global Recombinant Protein Drug R&D Companies Ranked by Revenue (2021) 4.1.2 Global Recombinant Protein Drug R&D Revenue by Player (2017-2022) 4.2 Global Recombinant Protein Drug R&D Concentration Ratio (CR) 4.2.1 Recombinant Protein Drug R&D Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Recombinant Protein Drug R&D in 2021 4.2.3 Global Recombinant Protein Drug R&D Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Recombinant Protein Drug R&D Headquarters, Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Type 4.3.1 Global Recombinant Protein Drug R&D Headquarters and Area Served 4.3.2 Global Recombinant Protein Drug R&D Companies Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Recombinant Protein Drug R&D Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Recombinant Protein Drug R&D Market Size by Company 4.5.1 Top Recombinant Protein Drug R&D Players in United States, Ranked by Revenue (2021) 4.5.2 United States Recombinant Protein Drug R&D Revenue by Players (2020, 2021 & 2022) 5 Global Recombinant Protein Drug R&D Market Size by Region 5.1 Global Recombinant Protein Drug R&D Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Recombinant Protein Drug R&D Market Size by Region (2017-2028) 5.2.1 Global Recombinant Protein Drug R&D Market Size by Region: 2017-2022 5.2.2 Global Recombinant Protein Drug R&D Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Recombinant Protein Drug R&D Market Size YoY Growth 2017-2028 6.1.2 North America Recombinant Protein Drug R&D Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 United States 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Recombinant Protein Drug R&D Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Recombinant Protein Drug R&D Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 China Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.3 Europe 6.3.1 Europe Recombinant Protein Drug R&D Market Size YoY Growth 2017-2028 6.3.2 Europe Recombinant Protein Drug R&D Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Recombinant Protein Drug R&D Market Size YoY Growth 2017-2028 6.4.2 Latin America Recombinant Protein Drug R&D Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Recombinant Protein Drug R&D Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Recombinant Protein Drug R&D Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 UAE 7 Company Profiles 7.1 Eli Lilly 7.1.1 Eli Lilly Company Details 7.1.2 Eli Lilly Business Overview 7.1.3 Eli Lilly Recombinant Protein Drug R&D Introduction 7.1.4 Eli Lilly Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.1.5 Eli Lilly Recent Development 7.2 Novo Nordisk 7.2.1 Novo Nordisk Company Details 7.2.2 Novo Nordisk Business Overview 7.2.3 Novo Nordisk Recombinant Protein Drug R&D Introduction 7.2.4 Novo Nordisk Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.2.5 Novo Nordisk Recent Development 7.3 Amgen 7.3.1 Amgen Company Details 7.3.2 Amgen Business Overview 7.3.3 Amgen Recombinant Protein Drug R&D Introduction 7.3.4 Amgen Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.3.5 Amgen Recent Development 7.4 Merck 7.4.1 Merck Company Details 7.4.2 Merck Business Overview 7.4.3 Merck Recombinant Protein Drug R&D Introduction 7.4.4 Merck Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.4.5 Merck Recent Development 7.5 Sanofi 7.5.1 Sanofi Company Details 7.5.2 Sanofi Business Overview 7.5.3 Sanofi Recombinant Protein Drug R&D Introduction 7.5.4 Sanofi Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.5.5 Sanofi Recent Development 7.6 Pfizer 7.6.1 Pfizer Company Details 7.6.2 Pfizer Business Overview 7.6.3 Pfizer Recombinant Protein Drug R&D Introduction 7.6.4 Pfizer Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.6.5 Pfizer Recent Development 7.7 Roche 7.7.1 Roche Company Details 7.7.2 Roche Business Overview 7.7.3 Roche Recombinant Protein Drug R&D Introduction 7.7.4 Roche Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.7.5 Roche Recent Development 7.8 Gensci 7.8.1 Gensci Company Details 7.8.2 Gensci Business Overview 7.8.3 Gensci Recombinant Protein Drug R&D Introduction 7.8.4 Gensci Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.8.5 Gensci Recent Development 7.9 Ankebio 7.9.1 Ankebio Company Details 7.9.2 Ankebio Business Overview 7.9.3 Ankebio Recombinant Protein Drug R&D Introduction 7.9.4 Ankebio Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.9.5 Ankebio Recent Development 7.10 United Cell 7.10.1 United Cell Company Details 7.10.2 United Cell Business Overview 7.10.3 United Cell Recombinant Protein Drug R&D Introduction 7.10.4 United Cell Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.10.5 United Cell Recent Development 7.11 Sinobioway Hygene 7.11.1 Sinobioway Hygene Company Details 7.11.2 Sinobioway Hygene Business Overview 7.11.3 Sinobioway Hygene Recombinant Protein Drug R&D Introduction 7.11.4 Sinobioway Hygene Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.11.5 Sinobioway Hygene Recent Development 7.12 Kexing 7.12.1 Kexing Company Details 7.12.2 Kexing Business Overview 7.12.3 Kexing Recombinant Protein Drug R&D Introduction 7.12.4 Kexing Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.12.5 Kexing Recent Development 7.13 Dongbao 7.13.1 Dongbao Company Details 7.13.2 Dongbao Business Overview 7.13.3 Dongbao Recombinant Protein Drug R&D Introduction 7.13.4 Dongbao Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.13.5 Dongbao Recent Development 7.14 3sbio 7.14.1 3sbio Company Details 7.14.2 3sbio Business Overview 7.14.3 3sbio Recombinant Protein Drug R&D Introduction 7.14.4 3sbio Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.14.5 3sbio Recent Development 7.15 Gan&Lee 7.15.1 Gan&Lee Company Details 7.15.2 Gan&Lee Business Overview 7.15.3 Gan&Lee Recombinant Protein Drug R&D Introduction 7.15.4 Gan&Lee Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.15.5 Gan&Lee Recent Development 7.16 Hengrui 7.16.1 Hengrui Company Details 7.16.2 Hengrui Business Overview 7.16.3 Hengrui Recombinant Protein Drug R&D Introduction 7.16.4 Hengrui Revenue in Recombinant Protein Drug R&D Business (2017-2022) 7.16.5 Hengrui Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Recombinant Protein Drug R&D Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Recombinant Protein Drug R&D Market Trends Table 3. Recombinant Protein Drug R&D Market Drivers Table 4. Recombinant Protein Drug R&D Market Challenges Table 5. Recombinant Protein Drug R&D Market Restraints Table 6. Global Recombinant Protein Drug R&D Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Recombinant Protein Drug R&D Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Recombinant Protein Drug R&D Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Recombinant Protein Drug R&D Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Recombinant Protein Drug R&D Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Recombinant Protein Drug R&D Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Recombinant Protein Drug R&D Revenue Share by Player, 2017-2022 Table 13. Global Recombinant Protein Drug R&D Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Recombinant Protein Drug R&D by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drug R&D as of 2021) Table 15. Top Players of Recombinant Protein Drug R&D in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Recombinant Protein Drug R&D Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Recombinant Protein Drug R&D Players in United States Market, Ranking by Revenue (2021) Table 20. United States Recombinant Protein Drug R&D Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Recombinant Protein Drug R&D Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Recombinant Protein Drug R&D Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Recombinant Protein Drug R&D Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Recombinant Protein Drug R&D Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Recombinant Protein Drug R&D Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Recombinant Protein Drug R&D Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Recombinant Protein Drug R&D Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Recombinant Protein Drug R&D Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Recombinant Protein Drug R&D Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Eli Lilly Company Details Table 31. Eli Lilly Business Overview Table 32. Eli Lilly Recombinant Protein Drug R&D Product Table 33. Eli Lilly Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 34. Eli Lilly Recent Development Table 35. Novo Nordisk Company Details Table 36. Novo Nordisk Business Overview Table 37. Novo Nordisk Recombinant Protein Drug R&D Product Table 38. Novo Nordisk Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 39. Novo Nordisk Recent Development Table 40. Amgen Company Details Table 41. Amgen Business Overview Table 42. Amgen Recombinant Protein Drug R&D Product Table 43. Amgen Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 44. Amgen Recent Development Table 45. Merck Company Details Table 46. Merck Business Overview Table 47. Merck Recombinant Protein Drug R&D Product Table 48. Merck Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 49. Merck Recent Development Table 50. Sanofi Company Details Table 51. Sanofi Business Overview Table 52. Sanofi Recombinant Protein Drug R&D Product Table 53. Sanofi Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 54. Sanofi Recent Development Table 55. Pfizer Company Details Table 56. Pfizer Business Overview Table 57. Pfizer Recombinant Protein Drug R&D Product Table 58. Pfizer Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 59. Pfizer Recent Development Table 60. Roche Company Details Table 61. Roche Business Overview Table 62. Roche Recombinant Protein Drug R&D Product Table 63. Roche Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 64. Roche Recent Development Table 65. Gensci Company Details Table 66. Gensci Business Overview Table 67. Gensci Recombinant Protein Drug R&D Product Table 68. Gensci Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 69. Gensci Recent Development Table 70. Ankebio Company Details Table 71. Ankebio Business Overview Table 72. Ankebio Recombinant Protein Drug R&D Product Table 73. Ankebio Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 74. Ankebio Recent Development Table 75. United Cell Company Details Table 76. United Cell Business Overview Table 77. United Cell Recombinant Protein Drug R&D Product Table 78. United Cell Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 79. United Cell Recent Development Table 80. Sinobioway Hygene Company Details Table 81. Sinobioway Hygene Business Overview Table 82. Sinobioway Hygene Recombinant Protein Drug R&D Product Table 83. Sinobioway Hygene Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 84. Sinobioway Hygene Recent Development Table 85. Kexing Company Details Table 86. Kexing Business Overview Table 87. Kexing Recombinant Protein Drug R&D Product Table 88. Kexing Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 89. Kexing Recent Development Table 90. Dongbao Company Details Table 91. Dongbao Business Overview Table 92. Dongbao Recombinant Protein Drug R&D Product Table 93. Dongbao Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 94. Dongbao Recent Development Table 95. 3sbio Company Details Table 96. 3sbio Business Overview Table 97. 3sbio Recombinant Protein Drug R&D Product Table 98. 3sbio Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 99. 3sbio Recent Development Table 100. Gan&Lee Company Details Table 101. Gan&Lee Business Overview Table 102. Gan&Lee Recombinant Protein Drug R&D Product Table 103. Gan&Lee Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 104. Gan&Lee Recent Development Table 105. Hengrui Company Details Table 106. Hengrui Business Overview Table 107. Hengrui Recombinant Protein Drug R&D Product Table 108. Hengrui Revenue in Recombinant Protein Drug R&D Business (2017-2022) & (US$ Million) Table 109. Hengrui Recent Development Table 110. Research Programs/Design for This Report Table 111. Key Data Information from Secondary Sources Table 112. Key Data Information from Primary Sources List of Figures Figure 1. Recombinant Protein Drug R&D Product Picture Figure 2. Global Recombinant Protein Drug R&D Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Recombinant Protein Drug R&D Market Size 2017-2028 (US$ Million) Figure 4. United States Recombinant Protein Drug R&D Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Recombinant Protein Drug R&D Market Size 2017-2028 (US$ Million) Figure 6. United States Recombinant Protein Drug R&D Market Share in Global 2017-2028 Figure 7. Recombinant Protein Drug R&D Report Years Considered Figure 8. Product Picture of Peptide Hormones Figure 9. Product Picture of Hematopoietic Factor Figure 10. Product Picture of Cytokines Figure 11. Product Picture of Plasma Protein Factor Figure 12. Product Picture of Recombinase Figure 13. Product Picture of Fusion Protein Figure 14. Product Picture of Other Figure 15. Global Recombinant Protein Drug R&D Market Share by Type in 2022 & 2028 Figure 16. Global Recombinant Protein Drug R&D Market Size by Type (2017-2028) & (US$ Million) Figure 17. Global Recombinant Protein Drug R&D Market Share by Type (2017-2028) Figure 18. United States Recombinant Protein Drug R&D Market Share by Type in 2022 & 2028 Figure 19. United States Recombinant Protein Drug R&D Market Size by Type (2017-2028) & (US$ Million) Figure 20. United States Recombinant Protein Drug R&D Market Share by Type (2017-2028) Figure 21. Product Picture of Diabetes Figure 22. Product Picture of Dwarfism Figure 23. Product Picture of Hemophilia Figure 24. Product Picture of Heart Disease Figure 25. Product Picture of Cancer Figure 26. Product Picture of Other Figure 27. Global Recombinant Protein Drug R&D Market Share by Application in 2022 & 2028 Figure 28. Global Recombinant Protein Drug R&D Market Size by Application (2017-2028) & (US$ Million) Figure 29. Global Recombinant Protein Drug R&D Market Share by Application (2017-2028) Figure 30. United States Recombinant Protein Drug R&D Market Share by Application in 2022 & 2028 Figure 31. United States Recombinant Protein Drug R&D Market Size by Application (2017-2028) & (US$ Million) Figure 32. United States Recombinant Protein Drug R&D Market Share by Application (2017-2028) Figure 33. North America Recombinant Protein Drug R&D Market Size Growth Rate 2017-2028 (US$ Million) Figure 34. United States Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Canada Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Europe Recombinant Protein Drug R&D Market Size Growth Rate 2017-2028 (US$ Million) Figure 37. Germany Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. France Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. U.K. Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. Italy Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Russia Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Asia-Pacific Recombinant Protein Drug R&D Market Size Growth Rate 2017-2028 (US$ Million) Figure 43. China Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Japan Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. South Korea Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. India Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Australia Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. China Taiwan Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Indonesia Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Thailand Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Malaysia Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. Latin America Recombinant Protein Drug R&D Market Size Growth Rate 2017-2028 (US$ Million) Figure 53. Mexico Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. Brazil Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 55. Argentina Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 56. Middle East & Africa Recombinant Protein Drug R&D Market Size Growth Rate 2017-2028 (US$ Million) Figure 57. Turkey Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 58. Saudi Arabia Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 59. UAE Recombinant Protein Drug R&D Market Size Growth Rate (2017-2028) & (US$ Million) Figure 60. Eli Lilly Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 61. Novo Nordisk Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 62. Amgen Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 63. Merck Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 64. Sanofi Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 65. Pfizer Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 66. Roche Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 67. Gensci Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 68. Ankebio Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 69. United Cell Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 70. Sinobioway Hygene Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 71. Kexing Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 72. Dongbao Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 73. 3sbio Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 74. Gan&Lee Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 75. Hengrui Revenue Growth Rate in Recombinant Protein Drug R&D Business (2017-2022) Figure 76. Bottom-up and Top-down Approaches for This Report Figure 77. Data Triangulation Figure 78. Key Executives Interviewed

Eli Lilly Novo Nordisk Amgen Merck Sanofi Pfizer Roche Gensci Ankebio United Cell Sinobioway Hygene Kexing Dongbao 3sbio Gan&Lee Hengrui